[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:diffuse-large-b-cell-lymphoma:cd19-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Diffuse Large B-Cell Lymphoma","CD19 Gene",21,[8,16,22,29,36,43,49,55,61,67,73,80,85,91,97,103,109,115,122,129,135],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05052528","Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[12],"Phase 1","RECRUITING","2026-08-26T02:18:52.966503Z","2026-05-05T02:35:31.778323Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05365659","IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas",[12],"2026-08-26T02:18:09.641312Z","2026-07-30T01:46:14.462340Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07283679","Phase I\u002FII Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.977643Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05633615","Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma",[33],"Phase 2","2026-08-26T02:18:23.582895Z","2026-05-05T02:43:27.059186Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT04512716","Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",[40],"Early Phase 1","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:26.957051Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT07042438","Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells",[33],"2026-08-26T02:15:11.740957Z","2026-05-05T02:35:31.730111Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05432635","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:16:07.529922Z","2026-04-29T02:57:57.084734Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[12],"2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[33],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[26],"2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":78,"content_modified":79},"NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",[77],"Phase 3","2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.052132Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":65,"content_modified":84},"NCT05077527","Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma",[12],"2026-05-05T02:43:29.044473Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[26],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.263994Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05672251","Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[33],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.249867Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06173518","A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",[12],"2026-08-26T02:17:21.315591Z","2026-05-05T02:35:31.644184Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT05281809","Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",[33],"2026-08-26T02:19:03.581490Z","2026-04-29T02:57:57.140676Z",{"nct_id":116,"title":117,"phases":118,"status":119,"updated_at":120,"content_modified":121},"NCT07676877","Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:09.452956Z","2026-07-05T03:45:20.439647Z",{"nct_id":123,"title":124,"phases":125,"status":126,"updated_at":127,"content_modified":128},"NCT03226704","Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:13.549512Z","2026-06-16T05:54:07.964568Z",{"nct_id":130,"title":131,"phases":132,"status":126,"updated_at":133,"content_modified":134},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[12],"2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z",{"nct_id":136,"title":137,"phases":138,"status":139,"updated_at":140,"content_modified":141},"NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",[26],"ACTIVE_NOT_RECRUITING","2026-08-03T03:30:50.548292Z","2026-05-05T02:43:29.152099Z"]